Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Exenatide.

Gillian M Keating1

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz

Drugs
|August 3, 2005
PubMed
Summary
This summary is machine-generated.

Exenatide, an incretin mimetic, significantly improved glycemic control and reduced body weight in adults with type 2 diabetes. These benefits were maintained long-term and comparable to insulin glargine in some studies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Afatinib in advanced NSCLC: a profile of its use.

Drugs & therapy perspectives : for rational drug selection and use·2019
Same author

Afatinib in advanced NSCLC: a profile of its use.

Drugs & therapy perspectives : for rational drug selection and use·2018
Same author

Ticagrelor: A Review in Long Term Secondary Prevention of Cardiovascular Events.

Drugs·2017
Same author

Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome.

Drugs·2017
Same author

Sorafenib: A Review in Hepatocellular Carcinoma.

Targeted oncology·2017
Same author

Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex<sup>®</sup>): A Review in Multiple Sclerosis-Related Spasticity.

Drugs·2017
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Exenatide is an incretin mimetic that regulates glucose metabolism through insulin secretion, glucagon suppression, and delayed gastric emptying.
  • Type 2 diabetes mellitus (T2DM) is a chronic condition requiring effective management strategies.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of exenatide in adults with T2DM and suboptimal glycemic control.
  • To compare exenatide's effectiveness against placebo and insulin glargine.

Main Methods:

  • Three large, randomized, placebo-controlled Phase III trials assessed subcutaneous exenatide (5 or 10 mcg twice daily) over 30 weeks.
  • A separate 26-week Phase III trial compared exenatide 10 mcg twice daily with insulin glargine in T2DM patients on metformin and sulfonylurea.

Related Experiment Videos

Main Results:

  • Exenatide significantly improved glycosylated hemoglobin (HbA1c) and reduced body weight compared to placebo.
  • These improvements were sustained for up to 82 weeks in post hoc analyses.
  • Exenatide demonstrated comparable glycemic control to insulin glargine when added to metformin and sulfonylurea therapy.

Conclusions:

  • Subcutaneous exenatide is an effective adjunctive therapy for improving glycemic control and reducing body weight in T2DM patients.
  • Exenatide is generally well-tolerated, with a similar risk of hypoglycemia to placebo when used with metformin, but a numerically higher risk when combined with sulfonylureas.